Phoenix News Desk

IS KIDNEY DISEASE A DEATH SENTENCE?

IS KIDNEY DISEASE A DEATH SENTENCE?

If you are diagnosed with kidney disease, it means your kidney’s are damaged and cannot filter your blood correctly.  This causes waste to build up in the body at an alarming and dangerous rate. If diagnosed with kidney disease, it increases your chances of having a stroke or heart attack. According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), 14% of the U.S. population suffers from chronic kidney disease (CDK). Kidney disease kills more people than breast or prostate cancer annually. In 2013, more than 47,000 Americans died from kidney disease.  NIDDK reported that the five-year survival rate for dialysis patients is only 35.8%, in comparison to a five-year survival rate of 85.5% for transplant patients. Approximately 3,000 new patients are added to the kidney transplant waiting list each month and 13 people die each day while waiting for a life-saving kidney transplant.

ENDONOVO THERAPEUTICS: CHANGING THE OUTCOME FOR KIDNEY DISEASE PATIENTS

Endonovo Therapeutics, Inc. (ENDV), a developer of non-invasive electroceuticals for the treatment of vascular diseases and inflammatory conditions in vital organs, announced last week that it has commenced a pre-clinical study to assess the therapeutic potential of its Immunotronics™ platform in the treatment of kidney disease. This platform aims to prevent and reverse inflammation and fibrosis in the kidneys. ENDV’s technology was shown to be a very potent anti-inflammatory device in a pre-clinical, pharmaceutical “gold standard” model of inflammation.

“We are excited to start our work on kidney disease and further expand our pipeline of non-invasive therapies targeting vascular diseases and inflammatory conditions in vital organs,” commented Endonovo CEO, Alan Collier.

This platform could truly transform the way we treat kidney disease patients and extend the lives of those affected, no longer making kidney disease a death sentence. ENDV’s Immunotronics™ platform is part of an emerging field called bioelectronic medicine, which seeks to harness electrical signals in the body to modulate the inflammatory reflex in order to treat deadly diseases without pills or chemo. ENDV’s technology is a non-invasive electroceutical device that harnesses magnetically-induced electrical field pathways in cells to illicit an anti-inflammatory response in tissues and organs. Endonovo is developing this non-invasive Electroceutical to reduce inflammation in vital organs in order to prevent organ failure and the need for transplants.

“Several kidney diseases have a strong inflammatory component and our aim is to demonstrate the anti-inflammatory and anti-fibrotic properties of our non-invasive electroceutical technology. Reversing inflammation in the kidneys that can cause injury, fibrosis and ultimately end-stage renal disease would represent a truly game changing application of bioelectronic medicine,” stated Mr. Collier.

It is vital to keep up-to-date on ENDV and their upcoming renal studies as they work tirelessly to change the biotech landscape. This pre-clinical renal study will be the first of several studies. Other renal origin studies coming up from EDNV include: including ischemia/reperfusion injury, acute kidney injury, and diabetic nephropathy.

IN OTHER BIOTECH NEWS…

CytRx Corporation (CYTR) a biopharmaceutical research and development company specializing in oncology, announced updates today on the regulatory pathway for a New Drug Application (NDA) submission for aldoxorubicin in soft tissue sarcomas (STS).

OncoMed Pharmaceuticals Inc. (OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, announced in May that their first patient has been dosed in the company’s Phase 1a clinical trial of anti-TIGIT (OMP-313M32), an investigational immuno-oncology therapeutic candidate intended to block suppression of the immune system in tumors and enable immune system anti-tumor activity.

Inovio Pharmaceuticals, Inc. (INO) announced today that it commenced its phase 3 clinical program to evaluate the efficacy of Inovio’s DNA-based immunotherapy, VGX-3100, to treat cervical dysplasia caused by human papillomavirus (HPV).

Earlier this month, Coherus BioSciences, Inc. (CHRS) announced that senior management will present at the 36thNASDAQ OMX Investor Program on Thursday, June 15, 2017 in London, UK. Coherus is a leading pure-play, global biosimilar company that develops and commercializes high-quality therapeutics for major regulated markets.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC. which owns Microcapspeculators.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC. which owns, Microcapspeculators.com may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC. which owns Microcapspeculators.com may be compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. For Full Legal Disclaimer Click Here.

Media Contact
Company Name: Microcap Speculators
Contact Person: Media Manager
Email: [email protected]
Phone: 1-702-720-6310
Country: United States
Website: http://microcapspeculators.com/